Jefferies analyst Martin Comtesse maintained a Buy rating on DocMorris today and set a price target of CHF12.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Martin Comtesse has given his Buy rating due to a combination of factors, primarily the company’s strong start to 2026, with first‑quarter revenue expanding by 10.7%, which is already at the high end of management’s full‑year growth ambitions. The prescription segment is a key driver, delivering CHF 68m of sales and posting both solid sequential momentum and very robust year‑on‑year expansion, underpinning confidence in the core business outlook.
In addition, the non‑prescription business has normalized after an exceptionally strong prior quarter yet continues to grow in line with strategic targets, suggesting the topline is well balanced across segments. Profitability is also improving meaningfully, with adjusted EBITDA narrowing its loss by nearly CHF 10m to –CHF 6.3m, leaving the company well positioned to reach break‑even by the fourth quarter, a milestone that should be particularly supportive for the equity story and valuation.
According to TipRanks, Comtesse is an analyst with an average return of -5.3% and a 37.42% success rate.